The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care
The Union Minister reviewed DST-supported SATHI-BHU facility
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
Subscribe To Our Newsletter & Stay Updated
